Skip to main navigation Skip to main content

Clin Mol Hepatol : Clinical and Molecular Hepatology

OPEN ACCESS
ABOUT
BROWSE ARTICLES
FOR CONTRIBUTORS

Articles

Original Article

Hepatocytic ankyrin repeat and SOCS box protein 3 deficiency alleviates metabolic dysfunction-associated steatotic liver disease by decreasing ubiquitin-mediated carnitine palmitoyl transferase 1A

Clinical and Molecular Hepatology 2025;31(4):1333-1354.
Published online: August 8, 2025

1Department of Laboratory Medicine and Central Laboratory of Huashan Hospital, Fudan University, Shanghai, China

2Department of Immunology and Department of Anatomy, Histoembryology, School of Basic Medical Sciences, Shanghai Medical College, Fudan University, Shanghai, China

3Department of Anatomy, Histoembryology, School of Basic Medical Sciences, Fudan University, Shanghai Medical College, Shanghai, China

4Division of Hematology, The Ohio State University Wexner Medical Center, the James Cancer Hospital, Columbus, OH, USA

Corresponding author : Dongqin Yang Department of Laboratory Medicine and Central Laboratory of Huashan Hospital, Fudan University, 12 Wulumuqi Middle Road, Shnaghai 200040, China Tel: +86-21-66895876, E-mail: kobesakura@fudan.edu.cn
Zuoyun Wang Department of Immunology and Department of Anatomy, Histoembryology, School of Basic Medical Sciences, Shanghai Medical College, Fudan University, 351 Room, Building 1, 131 Dong-An Road, Shanghai 200032, China Tel: +86-21-54237698, Fax: +86-21-54237698, E-mail: wangzuoyun@fudan.edu.cn
Chunhua Song Division of Hematology, The Ohio State University Wexner Medical Center, the James Cancer Hospital, 460 W. 12th Ave., Colubus, OH 43210, USA Tel: +1-614-2928715, Fax: +1-614-2937526, E-mail: chunhua.song@osumc.edu
Ming Guan Department of Laboratory Medicine and Central Laboratory of Huashan Hospital, Fudan University, 12 Wulumuqi Middle Road, Shanghai 200040, China Tel: +86-21-52889999, E-mail: guanming88@yahoo.com

These authors have contributed equally to this work.


Editor: Ja Hyun Koo, College of Pharmacy, Seoul National University, Korea

• Received: November 25, 2024   • Revised: July 14, 2025   • Accepted: August 6, 2025

Copyright © 2025 by The Korean Association for the Study of the Liver

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

  • 8,302 Views
  • 577 Download
  • 6 Web of Science
  • 8 Crossref
  • 6 Scopus
prev next

Citations

Citations to this article as recorded by  Crossref logo
  • Targeting the ASB3-CPT1A axis—a new player in combating metabolic dysfunction-associated steatotic liver disease: Editorial on “Hepatocytic ankyrin repeat and SOCS box protein 3 deficiency alleviates metabolic dysfunction-associated steatotic liver diseas
    Yueying Yang, Ying Yang, Yan Lu
    Clinical and Molecular Hepatology.2026; 32(2): 957.     CrossRef
  • The first genome-wide association study on pediatric obesity in Taiwan
    Hsin-Ru Wu, Ting-Yuan Liu, Chuan-Mu Chen, Fuu-Jen Tsai
    Journal of the Formosan Medical Association.2026;[Epub]     CrossRef
  • Correspondence to editorial 1 on “Hepatocytic ankyrin repeat and SOCS box protein 3 deficiency alleviates metabolic dysfunction-associated steatotic liver disease by decreasing ubiquitin-mediated carnitine palmitoyl transferase 1A”
    Yuli Lin, Dongqin Yang, Zhihao Wu, Ming Guan, Chunhua Song
    Clinical and Molecular Hepatology.2026; 32(3): e339.     CrossRef
  • Correspondence to editorial 2 on “Hepatocytic ankyrin repeat and SOCS box protein 3 deficiency alleviates metabolic dysfunction-associated steatotic liver disease by decreasing ubiquitin-mediated carnitine palmitoyl transferase 1A”
    Dongqin Yang, Yuli Lin, Chunhua Song, Ming Guan
    Clinical and Molecular Hepatology.2026; 32(3): e342.     CrossRef
  • ASB3 degrades the gateway to β-oxidation: Editorial on “Hepatocytic ankyrin repeat and SOCS box protein 3 deficiency alleviates metabolic dysfunction-associated steatotic liver disease by decreasing ubiquitin-mediated carnitine palmitoyl transferase 1A”
    Ho Jae Ryu, Ji Su Han, Ja Hyun Koo
    Clinical and Molecular Hepatology.2026; 32(3): 1379.     CrossRef
  • A multi-herb botanical formula ameliorates diet-induced non-alcoholic fatty liver disease associated with microbiota-dependent metabolic remodeling in mice
    Xinrui Meng, Fan Wang, Ying Li, Yan Li, Meiping Zhang, Jing Cong
    Food Research International.2026; 243: 120383.     CrossRef
  • ASB3 limits adipocyte thermogenesis and energy expenditure through p62 ubiquitination
    Mengyu Shi, Haoye Liu, Zhihao Wu, Linlin Huang, Chunhua Song, Yuli Lin, Dongqin Yang
    Metabolism.2026; 184: 156756.     CrossRef
  • Transcriptome and 16S rRNA analysis reveal the regulatory mechanisms underlying the differences in fat deposition between distinct broiler breeds
    Fang Wang, Wei Jing, Yuyang Xue, Shanshan Nan, Jinchao Liang, Cunxi Nie
    Journal of Advanced Research.2026;[Epub]     CrossRef

Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

Format:

Include:

Hepatocytic ankyrin repeat and SOCS box protein 3 deficiency alleviates metabolic dysfunction-associated steatotic liver disease by decreasing ubiquitin-mediated carnitine palmitoyl transferase 1A
Clin Mol Hepatol. 2025;31(4):1333-1354.   Published online August 8, 2025
Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

Format:
Include:
Hepatocytic ankyrin repeat and SOCS box protein 3 deficiency alleviates metabolic dysfunction-associated steatotic liver disease by decreasing ubiquitin-mediated carnitine palmitoyl transferase 1A
Clin Mol Hepatol. 2025;31(4):1333-1354.   Published online August 8, 2025
Close

Figure

  • 0
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
Hepatocytic ankyrin repeat and SOCS box protein 3 deficiency alleviates metabolic dysfunction-associated steatotic liver disease by decreasing ubiquitin-mediated carnitine palmitoyl transferase 1A
Image Image Image Image Image Image Image Image
Figure 1. Effect of ASB3 on lipid accumulation in the liver. (A, B) Comparison of HFD-fed ASB3 HO mice (ASB3 HO-HFD) and WT (WTHFD) mice based on body weight (A) and mean body weight at 8 and 16 weeks (B). (C, D) Representative images of H&E staining (C) and quantification of Oil Red O-stained areas (D) in liver tissue from ASB3 HO-HFD mice vs. WT-HFD mice. The top panel is at low magnification, and the bottom panel is at high magnification. The black arrow points to the ballooning degeneration. (E, F) Representative images of FFA-induced percentages of Oil Red O-stained areas (E) and representative images and quantification of neutral lipid droplets stained with BODIPY (F) in hepatocytes from ASB3 HO-HFD and WT-HFD mice. n=3–5 per group. FFA, free fatty acid; HFD, high-fat diet; HO, homozygous; WT, wild-type. *P<0.05, **P<0.01, ***P<0.001.
Figure 2. ASB3 deficiency disrupts lipid accumulation by increasing fatty acid oxidation. (A, B) Dynamic changes in oxygen consumption (OCR) during the night (dark) and day (light) periods and comparisons of OCR during the dark, light, and total periods (A) and the results of the glucose tolerance test and insulin tolerance test (B) in ASB3 HO-HFD and WT-HFD mice. (C, D) Quantitative analysis of basic OCR and maximum respiration OCR and Western blot showing ASB3 expression upon ASB3 shRNA (shASB3) treatment vs. scramble shRNA (shNC) in Huh7 cells (C) and OCR profiles and quantification of maximum respiration in vector control Huh7 cells and ASB3-OE cells exposed to PA (D). (E, F) Volcano plot of differentially expressed genes (DEGs) (E) GO enrichment analysis of DEGs (F) in the RNA-seq data of shNC- and shASB3-transfected Huh7 cells. n=5 per group. HFD, high-fat diet; HO, homozygous; PA, palmitate; WT, wild-type. *P<0.05, ***P<0.001, ****P<0.0001, ns, not significant.
Figure 3. ASB3 regulates CPT1A ubiquitination via direct interactions. (A) Schematic overview of the proteomic quantification approach for identifying lysine ubiquitylation profiles. Summary of the functional landscape and ubiquitination targets identified in our study. Equal amounts of cell lysates (7.5 mg) from shASB3 and shNC cells were used. The diglycine (diGly)-modified lysine and its position are indicated. Here, y1, y2, y3, y4, y5, y6, y7, and y8 are c-terminal fragment y-ion series; b1, b2, b3, and b6 are the N-terminal fragment b-ion series. (B) Immunoblotting images of the interaction of ASB3 with CPT1A in HEK293T cells. (C) ASB3 induces CPT1A ubiquitination in HEK293T cells with or without MG132 (left) and in the hepatocytes of ASB3HKO vs. ASB3fl/fl mice fed an NCD or HFD (right). (D) Identification of the subdomains of ASB3 that induce CPT1A ubiquitination. (E) Effects of CPT1A mutants on ASB3-induced ubiquitination. (F) Identification of subdomains in ASB3 or CPT1A involved in their interactions. HEK293T cells were transfected with the indicated plasmids. ASB3, ankyrin repeat and SOCS box protein 3; CPT1A, carnitine palmitoyl transferase 1A; HFD, high-fat diet; NCD, normal chow diet.
Figure 4. CPT1A-dependent ASB3 regulation of lipid accumulation and FAO. (A) PCA and volcano map analysis of differentially abundant metabolites in the livers of ASB3HKO and ASB3fl/fl mice. (B, C) Comparison of CPT1A RNA (B) and protein (C) levels in the livers of ASB3HKO and ASB3fl/fl mice. (D) Comparison of FFA-induced generation of lipid droplets in hepatocytes from ASB3HKO and ASB3fl/fl mice after treatment with the CPT1A inhibitor etomoxir (Eto, 3 μM) or the DMSO control, as determined using Oil Red O and BODIPY staining. (E, F) Hepatocytes from ASB3HKO and ASB3fl/fl mice were isolated, cultured, and induced with FFA for 8 hours following treatment with Eto or DMSO. (E) Comparison of TG contents in hepatocytes from ASB3HKO and ASB3fl/fl mice. (F) Quantitative analysis of OCR in shASB3-PA vs. shNC-PA cells treated with Eto. n=5 per group. ASB3, ankyrin repeat and SOCS box protein 3; CPT1A, carnitine palmitoyl transferase 1A; FAO, fatty acid oxidation; FFA, free fatty acid; OCR, oxygen consumption; PA, palmitate; PCA, principal component analysis; TG, triglycerides. *PP<0.05, **PP<0.01, ***PP<0.001, ns, not significant.
Figure 5. Hepatocyte-specific ASB3 knockout prevents HFD-induced MASLD in a CPT1A-dependent manner. (A) Comparison of body weight curves and body weights at 20 weeks in the ASB3fl/fl control-AAV shNC (CTL-shNC), ASB3HKO-AAV shNC (HKO-shNC), ASB3fl/fl control-AAV shCPT1A (CTL-shCPT1A), and ASB3HKO-AAV shCPT1A (HKO-shCPT1A) groups (n=5). (B) Comparison of liver images, liver weights, and proportions of liver weight per body weight in the CTL-shNC, HKO-shNC, CTL-shCPT1A, and HKO-shCPT1A groups. (C–F) Comparison of the lipid droplet areas in the liver tissues stained with H&E (C) and oil red O (D) as well as the quantification of oil red O staining (E) and FAO activity (F) in the CTL-shNC, HKO-shNC, CTL-shCPT1A, and HKO-shCPT1A groups. The black arrow points to the lipid vacuole area. n=3–5 per group. ASB3, ankyrin repeat and SOCS box protein 3; CPT1A, carnitine palmitoyl transferase 1A; HFD, high-fat diet; MASLD, metabolic dysfunction-associated steatotic liver disease. *P<0.05, **P<0.01, ns, not significant.
Figure 6. Hepatocyte-specific ASB3 knockout delays MCD-induced and GAN-induced MASLD. (A) Comparison of body weight, liver weight, liver weight/body weight ratio, and serum biomarkers of hepatic ALT and AST function between ASB3fl/fl and ASB3HKO mice fed MCD diets for 5 weeks. (B) Representative hepatic images, H&E and Oil Red O staining, lipid droplet diameters, and lipid droplet areas in the livers of ASB3fl/fl and ASB3HKO mice fed an MCD diet. The black arrow points to the lipid vacuole area. (C, D) Representative images of Sirius Red-stained samples from ASB3fl/fl and ASB3HKO mice and the mRNA levels of fibrosis markers (Col1a1 and Acta2) (C) and inflammation genes (Tnf, Il1b, and Il6) (D) in ASB3fl/fl and ASB3HKO mice fed MCD diets. (E) Body weight, liver weight, and liver/body weight ratio between ASB3fl/fl and ASB3HKO mice fed with GAN diets. (F) Representative images of H&E and Oil Red O staining and quantification of the Oil Red O staining area in ASB3fl/fl and ASB3LHKO mice fed with GAN diets. n=3–6 for in vivo studies. ALT, alanine aminotransferase; AST, aspartate aminotransferase; MCD, methionine-choline deficiency; MASLD, metabolic dysfunction-associated steatotic liver disease. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001.
Figure 7. Increased ASB3 expression in the liver tissues of MASLD patients. (A) Comparison of ASB3 and CPT1A IHC staining in MASLD patients and healthy controls and quantification of the data. (B) Comparison of ASB3 and CPT1A IHC staining and quantities in mice fed NCD, MCD and GAN diets. n=5 per group. (C) Analysis of ASB3 expression in a cohort of MASLD patients categorized by fibrosis extent using the SteatoSITE dataset. (D) Correlation analysis between CPT1A and ASB3 expression in MASLD patients from the GSE135251 dataset. (E) Correlation analysis of IRS1, IRF1, CPT1A, and ASB3 expression in MASLD patients from the GSE135251 dataset. (F) A model indicating that ASB3-mediated CPT1A degradation hampers FAO and facilitates lipid accumulation to promote MASLD and that ASB3 disruption stabilizes CPT1A and enhances FAO to prevent MASLD and obesity. ASB3, ankyrin repeat and SOCS box protein 3; CPT1A, carnitine palmitoyl transferase 1A; FAO, fatty acid oxidation; MASLD, metabolic dysfunction-associated steatotic liver disease; MCD, methionine-choline deficiency; NCD, normal chow diet; TG, triglycerides. *P<0.05, **P<0.01, ***P<0.001.
Graphical abstract
Hepatocytic ankyrin repeat and SOCS box protein 3 deficiency alleviates metabolic dysfunction-associated steatotic liver disease by decreasing ubiquitin-mediated carnitine palmitoyl transferase 1A